Erasca ERAS
NASDAQ ERAS
$16.11 -0.15 (-0.92%)
As of: Sep 4, 2026 · 1:40 PM EDT

Erasca (ERAS) Income towards Parent Company (2020 - 2026)

Erasca's (ERAS) quarterly Income towards Parent Company came in at -$860.7 million in Q1 2026, down 2218.06% YoY from $40.6 million in Q1 2025, and down 2423.74% on a QoQ basis from -$34.1 million in Q4 2025.

Analysis

Erasca (ERAS) Income towards Parent Company (2020 - 2026) Analysis & Trends

Erasca (ERAS) has 7 years of Income towards Parent Company data on file, last reported at -$860.7 million in Q1 2026.

  • Quarterly Income towards Parent Company fell 2218.06% year-over-year to -$860.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 billion (down 267.67% YoY) and the FY2025 annual result came in at -$383.1 million, down 98.94% from the prior year.
  • Income towards Parent Company retreated to -$860.7 million in Q1 2026, from -$34.1 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$29.4 million in Q4 2023 to a low of -$860.7 million in Q1 2026.
  • A 5-year average of -$118.3 million and a median of -$55.7 million in 2025 frame the typical range for Income towards Parent Company.
  • Annual changes were most pronounced in 2023 — Income towards Parent Company surged 78.8% — and 2026, when it slumped 2218.06%.
  • Tracing ERAS's Income towards Parent Company over 5 years: stood at -$138.7 million in 2022, then surged by 78.8% to -$29.4 million in 2023, then dropped by 27.25% to -$37.4 million in 2024, then advanced by 8.84% to -$34.1 million in 2025, then tumbled by 2423.74% to -$860.7 million in 2026.
  • The last three Income towards Parent Company figures came in at -$860.7 million (Q1 2026), -$34.1 million (Q4 2025), and -$51.1 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn -
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn -
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn
10 Erasca 5.02 Bn 5.02 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -44.08 Mn
Mar 31, 2026 -183.46 Mn
Dec 31, 2025 -29.04 Mn
Sep 30, 2025 -30.58 Mn
Jun 30, 2025 -33.88 Mn
Mar 31, 2025 -30.97 Mn
Dec 31, 2024 -30.43 Mn
Sep 30, 2024 -31.37 Mn
Jun 30, 2024 -63.20 Mn
Mar 31, 2024 -35.02 Mn
Dec 31, 2023 -29.70 Mn
Sep 30, 2023 -30.36 Mn
Jun 30, 2023 -31.78 Mn
Mar 31, 2023 -33.20 Mn
Dec 31, 2022 -135.25 Mn
Sep 30, 2022 -35.49 Mn
Jun 30, 2022 -35.61 Mn
Mar 31, 2022 -36.46 Mn
Dec 31, 2021 -30.97 Mn
Sep 30, 2021 -46.07 Mn